Low Hepsin Expression Associates with a Better Response to Gemcitabine-Based Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
A low hepsin expression following neoadjuvant therapy is associated with a better treatment response among those receiving gemcitabine-based treatment. Thus, hepsin does not appear to influence prognosis in pancreatic cancer patients, regardless of whether they received neoadjuvant therapy or not.
Authors
- Topi Aulis Tervonen
- Jaana Hagström (ORCID: https://orcid.org/0000-0001-6079-7881)
- Malin Sund (ORCID: https://orcid.org/0000-0002-7516-9543)
- Hanna Seppänen (ORCID: https://orcid.org/0000-0002-2529-651X)
- Caj Haglund (ORCID: https://orcid.org/0000-0003-0456-4965)
- Juha Klefström (ORCID: https://orcid.org/0000-0001-7124-8431)
- Harri Mustonen (ORCID: https://orcid.org/0000-0001-5632-6796)
- Sini Vahtera
Institutions
- University of Helsinki (FI)
- University of Turku (FI)
- University of California, San Francisco (US)
- Helsinki University Hospital (FI)
Publication Details
- Journal
- Oncology
- Published
- 2025-08-25
- DOI
- https://doi.org/10.1159/000547820
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00